Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic
Top Cited Papers
Open Access
- 25 April 2005
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 165 (8) , 936-946
- https://doi.org/10.1001/archinte.165.8.936
Abstract
The prevalence of end-stage renal disease (ESRD) has doubled in the United States during the last decade and is expected to double again by the year 2010.1 Patients with ESRD experience substantial cardiovascular morbidity and mortality; in ad-dition, health costs related to ESRD exceed $12 billion annually.1 It is estimated that more than 10 million Americans have chronic kidney disease and are at high risk of developing ESRD.2 Therefore, therapeutic interventions that slow decline in renal function in patients with chronic kidney disease are important.3Keywords
This publication has 2 references indexed in Scilit:
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39BMJ, 1998